Control of Refractory Resistant Cytomegalovirus Viremia After Belatacept Withdrawal in a High-Risk Kidney Transplant Recipient (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1137; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Maintenance immunosuppression consisted of belatacept, mycophenolate sodium, and prednisone...Valganciclovir was escalated to treatment dosing and mycophenolate was held, with transient viral suppression followed by recurrent viremia...Resistance testing demonstrated ganciclovir and cidofovir resistance and preserved susceptibility to maribavir, foscarnet, and letermovir...Belatacept was discontinued, and transitioned to sirolimus with prednisone...Despite active antiviral therapy, virologic control was not achieved until belatacept discontinuation, suggesting that impaired CMV-specific cellular immunity may have contributed substantially to persistent infection. This case highlights the need to reassess immunosuppression alongside antiviral therapy in refractory CMV infection."
Clinical • ANCA Vasculitis • Chronic Kidney Disease • Cytomegalovirus Infection • Infectious Disease • Transplantation • Vasculitis • CD80
|
|
Boonyanuth N. Maturostrakul; Krishna A. Agarwal; Esteban A. DelPilar Morales; Urmee Saha; Armando Paez
|